Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pinto, A. E.
Right arrow Articles by Soares, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pinto, A. E.
Right arrow Articles by Soares, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:525-533, 2001
© 2001 European Society for Medical Oncology

research-article

c-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis

A. E. Pinto1,, S. André1, T. Pereira1, S. Nóbrega2 and J. Soares1

1Departamento de Patologia Morfologica e Centro de Investigacão de Patobiologia Molecular do Instituto Portugués de Oncologia de Francisco Gentil Portugal
2Registo Oncologico Regional (ROR-Sul) do Instituto Portugues de Oncologia de Francisco Gentil, Centro de Lisboa Portugal

Correspondence to: A E Pinto, MD, Departamento de Patologia Morfológica, Instituto Português de Oncologia Francisco Gentil, Rua Prof Lima Basto, 1099-023 Lisboa Codex, Portugal

Purpose To investigate the predictive value of c-erbB-2 oncoprotein expression as compared with established histopathological and cytometric indicators of disease evolution in breast carcinoma

Patients and methods A short-term retrospective study was conducted on a series of 306 breast cancer patients Classic prognostic factors included tumour size, nodal involvement, histological grading, and hormone receptor status. Flow cytometric DNA ploidy and S-phase fraction (SPF) were also assessed. A Cox proportional hazards regression model was used for multivariate statistical analysis

Results c-erbB-2 overexpression was present in 43 out of 295 (14 6%) tumours, and showed a statistically significant correlation with high histological grade, DNA aneuploidy, high SPF and lack of estrogen receptors (ER) Univariate analysis revealed its association with worse disease-free survival (DFS) and overall survival (OS) The combined evaluation of c-erbB-2 with ploidy and SPF defines a variable (P + S + c) that showed a significant correlation with disease outcome By multivariate analysis, only nodal status (P < 0 001) and P + S + c subgrouping (group 2 P = 0 002, group 3 P = 0 001) in relation to DFS, and nodal status (P = 0 001) and DNA ploidy (P = 0 006) in relation to OS, retained independent prognostic significance Subset analyses showed that cytometric parameters, P + S + c subgrouping and hormone receptors were significantly correlated with disease outcome in node-positive patients, whereas in node-negative subgroup no prognostic indicators were found c-erbB-2 overexpression exhibited a trend in node-positive breast cancer (DFS P = 0 068, OS. P = 0.086), and significant correlation with poor clinical evolution in ER positive patients (DFS P = 0 015, OS P = 0 004), mostly receiving tamoxifen

Conclusions c-erbB-2 is an independent prognostic indicator of DFS when evaluated in conjunction with ploidy and SPF It also seems to predict response to tamoxifen therapy, by identifying a subgroup of ER positive (ER+) breast cancer patients with poor prognosis

breast carcinoma, c-erbB-2 expression, immunohistochemistry, prognosis, therapy response prediction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist, April 1, 2009; 14(4): 320 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. J. Filardo, C. T. Graeber, J. A. Quinn, M. B. Resnick, D. Giri, R. A. DeLellis, M. M. Steinhoff, and E. Sabo
Distribution of GPR30, a Seven Membrane-Spanning Estrogen Receptor, in Primary Breast Cancer and its Association with Clinicopathologic Determinants of Tumor Progression.
Clin. Cancer Res., November 1, 2006; 12(21): 6359 - 6366.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Jackisch
HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy
Oncologist, September 1, 2006; 11(suppl_1): 34 - 41.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein
Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pathol.Home page
I Guerra, J Algorta, R Diaz de Otazu, A Pelayo, and J Farina
Immunohistochemical prognostic index for breast cancer in young women
Mol. Pathol., December 1, 2003; 56(6): 323 - 327.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Oncologist, August 1, 2003; 8(4): 307 - 325.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.